<- Go Home
Vical Incorporated
As of August 31, 2019, Vical Incorporated was acquired by Brickell Biotech, Inc., in a reverse merger transaction. Vical Incorporated researches and develops biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company was founded in 1987 and is headquartered in San Diego, California.
Market Cap
$15.3M
Volume
26.2K
Cash and Equivalents
$10.8M
EBITDA
-$13.3M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$6.8M
Profit Margin
4000.00%
52 Week High
$10.29
52 Week Low
$4.20
Dividend
N/A
Price / Book Value
0.37
Price / Earnings
-1.22
Price / Tangible Book Value
0.37
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$13.3M
Return on Equity
25.49%
Return on Assets
-16.73
Cash and Short Term Investments
$41.7M
Debt
N/A
Equity
$41.5M
Revenue
$171.0K
Unlevered FCF
-$9.3M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium